ENGN Stock Analysis: enGene Holdings Common Stock | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 121m USD | 12M Return: -73.7% | CA29286X1015 | Charts, Fundamentals & Technical Analysis

Genetic Medicines, Bladder Cancer, Clinical Trials
Total Rating 22
Safety 54
Buy Signal -0.78
Biotechnology
Sub-Industry Rotation: +4.7
Market Cap: 121M
Avg Turnover: 1.47M
Risk 3d forecast
Volatility227%
VaR 5th Pctl31.1%
VaR vs Median-11.7%
Reward TTM
Sharpe Ratio-0.23
Rel. Str. IBD27.3
Rel. Str. Peer Group39 pctl
Character TTM
Beta1.367
Beta Downside1.793
Hurst Exponent0.510
Choppyness43.3%
Drawdowns 3y
Max DD92.11%
CAGR/Max DD-0.37
CAGR/Mean DD-0.57

Warnings

Strong Share Dilution
Interest Coverage Ratio Critical
Overextended 3d
Below Sma 200d

Tailwinds

Ep Pivot

Seasonality

Not enough history
Description: ENGN enGene Holdings Common Stock

enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage biotechnology company developing genetic medicines.

The company focuses on treatments for bladder cancer, a disease with significant unmet medical needs in oncology. Its primary candidate, detalimogene voraplasmid, is a monotherapy for non-muscle invasive bladder cancer (NMIBC), currently in Phase 2 clinical trials. The biotechnology sector is characterized by lengthy and capital-intensive drug development processes.

To deepen your understanding of enGenes financial health and market position, consider exploring its comprehensive analysis on ValueRay.

Headlines to Watch Out For
  • Detaligene voraplasmid clinical trial results impact stock
  • Regulatory approval for NMIBC treatment drives valuation
  • Competition in bladder cancer market affects sales
  • Pipeline development success expands future revenue streams
Piotroski VR-10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.36 > 0.02 and ΔFCF/TA 2.67 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.36 > 3% & CFO -103.3m > Net Income -4.90m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.21 > 1.5 & < 3
Outstanding Shares: last quarter (69.7m) vs 12m ago 36.47% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.20%; Δ -0.20% > 0%)
Interest Coverage Ratio: -43.20 > 6 (EBIT TTM -132.6m / Interest Expense TTM 3.07m)
Altman Z'' 1.28
A: 0.87 (Total Current Assets 277.9m - Total Current Liabilities 27.2m) / Total Assets 288.3m
B: -1.61 (Retained Earnings -464.5m / Total Assets 288.3m)
C: -0.50 (EBIT TTM -132.6m / Avg Total Assets 266.9m)
D: 3.97 (Book Value of Equity 230.3m / Total Liabilities 58.0m)
Altman-Z'' = 1.28 = BB
What is the price of ENGN shares?

As of November 13, 2026, the stock is trading at USD 2.28 with a total of 11,868,706 shares traded. Over the past week, the price has changed by +35.71%, over one month by +34.12%, over three months by +34.12% and over the past year by -73.73%.

Current recommended Stop Loss: 2.10 (which is 7.9% or 1.6 ATR below the current price).

Is ENGN a buy, sell or hold?

enGene Holdings Common Stock has received a consensus analysts rating of 3.56. Therefore, it is recommended to hold ENGN.

  • StrongBuy: 2
  • Buy: 1
  • Hold: 6
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ENGN price?
Analysts Target Price 3.9 69.3%
enGene Holdings Common Stock (ENGN) - Fundamental Data Overview as of 13 November 2026
Market Cap USD = 120.6m (120.6m USD * 1.0 USD.USD)
P/B = 0.5267
Revenue TTM = 0.0 USD
EBIT TTM = -132.6m USD
EBITDA TTM = -131.9m USD
Long Term Debt = 25.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.45m USD (from shortTermDebt, last quarter)
Debt = 41.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.92m
Net Debt = -225.1m USD (calculated: Debt 41.2m - CCE 266.3m)
Enterprise Value = 120.6m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = -43.20 (Ebit TTM -132.6m / Interest Expense TTM 3.07m)
EV/FCF = -1.16x (Enterprise Value 120.6m / FCF TTM -104.0m)
FCF Yield = -86.21% (FCF TTM -104.0m / Enterprise Value 120.6m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 718k) / Revenue TTM)
 Tobins Q-Ratio = 0.42 (Enterprise Value 120.6m / Total Assets 288.3m)
Interest Expense / Debt = 7.45% (Interest Expense 3.07m / Debt 41.2m)
Taxrate = 0.0% (0.0 / 32.5m)
NOPAT = -132.6m (EBIT -132.6m * (1 - 0.00%)) [loss with tax shield]
Current Ratio = 10.21 (Total Current Assets 277.9m / Total Current Liabilities 27.2m)
Debt / Equity = 0.18 (Debt 41.2m / totalStockholderEquity, last quarter 230.3m)
 Debt / EBITDA = 1.71 (negative EBITDA) (Net Debt -225.1m / EBITDA -131.9m)
 Debt / FCF = 2.16 (negative FCF - burning cash) (Net Debt -225.1m / FCF TTM -104.0m)
 Total Stockholder Equity = 233.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.84% (Net Income -4.90m / Total Assets 288.3m)
RoE = -2.10% (Net Income TTM -4.90m / Total Stockholder Equity 233.7m)
RoCE = -51.24% (EBIT -132.6m / Capital Employed (Equity 233.7m + L.T.Debt 25.2m))
 RoIC = -50.32% (negative operating profit) (NOPAT -132.6m / Invested Capital 263.6m)
 WACC = 9.52% (E(120.6m)/V(161.8m) * Re(10.23%) + D(41.2m)/V(161.8m) * Rd(7.45%) * (1-Tc(0.0)))
Discount Rate = 10.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.84 | Cagr: 28.82%
 [DCF] Fair Price = unknown (Cash Flow -104.0m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2027-01-31): EPS=-0.38 | Chg30d=-10.79% | Revisions=-50% | Analysts=3
EPS current Year (2026-10-31): EPS=-1.82 | Chg30d=-0.61% | Revisions=-36% | GrowthEPS=+20.5% | GrowthRev=+0.0%
EPS next Year (2027-10-31): EPS=-1.59 | Chg30d=-9.67% | Revisions=-10% | GrowthEPS=+12.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -38% (up=5, down=13)